Profilo
David Dornan is Chief Scientific Officer at Whitehawk Therapeutics, Inc. since 2025.
Former roles include Chief Scientific Officer at Elevation Oncology, Inc. from 2022 to 2025, Senior Vice President-Research & Manufacturing at Bolt Biotherapeutics, Inc. from 2019 to 2022, and Director & Head-Oncology Research at Gilead Sciences, Inc. from 2012 to 2017.
Education includes a doctorate from the University Of Dundee and an undergraduate degree from the University of Strathclyde.
Posizioni attive di David Dornan
| Società | Posizione | Inizio |
|---|---|---|
| WHITEHAWK THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 18/02/2025 |
Precedenti posizioni note di David Dornan
| Società | Posizione | Fine |
|---|---|---|
| ELEN ONCO | Direttore Tecnico/Scientifico/R&S | 17/02/2025 |
| BOLT BIOTHERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 11/03/2022 |
| GILEAD SCIENCES, INC. | Direttore/Membro del Consiglio | 01/11/2017 |
Formazione di David Dornan
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 6 |
|---|---|
Gilead Sciences, Inc.
Gilead Sciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes therapeutic products and treatments for life threatening diseases | Health Technology |
University Of Dundee
University Of Dundee Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Strathclyde
University of Strathclyde Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage immuno-oncology company | Health Technology |
Elevation Oncology, Inc.
Elevation Oncology, Inc. Pharmaceuticals: MajorHealth Technology Develops elevating precision medicines for cancer treatment | Health Technology |
Aadi Bioscience, Inc.
Aadi Bioscience, Inc. BiotechnologyHealth Technology Develops mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases | Health Technology |
















